Oncolytic Virus Therapy Landscape Expands with Over 100 Companies Leading the Charge in Pioneering New Treatments.
ByAinvest
Wednesday, Feb 4, 2026 5:44 pm ET1min read
CADL--
ONCY--
DelveInsight's Oncolytic Virus Competitive Landscape 2026 report highlights a robust oncolytic virus pipeline with 100+ active players developing 110+ drugs. Key companies such as Oncolytics Biotech, SillaJen, Candel Therapeutics, and others are evaluating new oncolytic virus drugs. Promising therapies like Pelareorep, Pexa-Vec, and CAN-2409 are in different phases of clinical trials. The market is driven by growing cancer incidence, increasing understanding of cancer biology, advancements in viral engineering, and rising adoption of personalized medicine.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet